Access to Innovative Treatments Act of 2023
- Introduced Mar 30
- Committee Mar 30
- Passed House Next
- Passed Senate Not yet
- To President Not yet
- Law Not yet
Companies lobbying on this bill
1 companyVotes
No recorded roll-call vote on this bill yet
Member trades
No member of Congress traded these companies in the last 90 days
Summary
Access to Innovative Treatments Act of 2023
Full summary2 paragraphs
This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. (Under the bill, adverse national coverage determinations are denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration.) The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.
The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.
Library of Congress summary, Mar 30, 2023
- Introduced in HouseMar 30, 2023
Actions
- HouseReferred to the Subcommittee on Health.Dec 17, 2024
- HouseReferred to the Subcommittee on Health.Apr 7, 2023
- HouseIntroduced in HouseMar 30, 2023
- HouseReferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Mar 30, 2023
Bill record
Text versions1
- Introduced in HouseMar 30, 2023PDF: Introduced in House
Committees2
- House Ways and Means CommitteeReferred To Mar 30, 2023
- Subcommittee: Health SubcommitteeReferred to
- House Energy and Commerce CommitteeReferred To Mar 30, 2023
- Subcommittee: Health SubcommitteeReferred to
Sponsor and cosponsors1 cosponsor
- Rep. Nanette Barragan (D-CA-44)Sponsor, Mar 30, 2023
- John Joyce (R-PA-13)OriginalJoined Mar 30, 2023
Amendments0
No amendments offered
Cost estimates and reports0
No cost estimate or committee report yet
Titles2
- Access to Innovative Treatments Act of 2023Short Title(s) as Introduced
- To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.Official Title as Introduced
Subjects1
Related bills1
- H.R. 9358 117th, Reintroduction of Access to Innovative Treatments Act of 2022
Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.